Blinatumomab for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 29 May 2015: Trial registered, NCT02458014
  2. 14 Sep 2015: Trial started, NCT02458014

The trials

NCT00560794: Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

State
Completed
Phase
Phase 2
People
21 taking part
Started
Jan 2008
Primary completion
Sep 2009
Arms
Blinatumomab
Results
Posted on the registry
  1. 20 Nov 2007: Trial registered
  2. 7 Jan 2015: Trial results posted

NCT02458014: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

State
Completed
Phase
Phase 2
People
37 taking part
Started
14 Sep 2015
Primary completion
16 Sep 2025
Arms
Treatment (blinatumomab)
Results
Posted on the registry
  1. 29 May 2015: Trial registered
  2. 14 Sep 2015: Trial started
  3. 16 Sep 2025: Trial completed
  4. 25 Sep 2026: Trial results posted

NCT04785547: ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

State
Stopped early
Phase
Phase 2
People
3 taking part
Started
17 Dec 2020
Primary completion
22 Jan 2022
Arms
Blincyto
Results
None posted
  1. 17 Dec 2020: Trial started
  2. 8 Mar 2021: Trial registered
  3. 22 Jan 2022: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Blincyto, Blinatumomab (MT103).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.